XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…

Slides:



Advertisements
Similar presentations
What, Where, How and Action Steps… XDR-TB
Advertisements

TB and HIV: Tightly Linked… and Why We Should Care.
Vaccine in National Immunization Programme Update March 2015.
World Health Organization
Technical Advisory Group meeting, WHO/WPRO
Tuberculosis quick facts Illustrated through drawings from children across the Region Philippines.
Advocacy, Communication, and Social Mobilization to Fight XDR TB
What, Where, How and Action Steps… XDR-TB
TITLE from VIEW and SLIDE MASTER | August 7, |1 | Countries with Hib vaccine in the national immunization programme; and planned introductions *
4 th National Anti-tuberculosis Drug Resistance Survey Botswana, 2007.
Thank you for viewing this presentation.
The Global Plan to Stop TB, (1)
1 Global and Regional Tuberculosis (TB) update ACSM workshop, Amman, Jordan April 13-17, 2008 Dr. Sevil Huseynova.
22 March 2012 Europe and ACP together against tuberculosis European Parliament, Rue Wiertz 60 BRUSSELS Charles S Mgone EDCTP Executive Director.
THE FIGHT TO STOP TB WHAT ARE WE FIGHTING? TUBERCULOSIS: THE WORLD’S NO. 1 KILLER AMONG CURABLE, INFECTIOUS DISEASES But there is hope PEOPLE WHO HAVE.
DRUG-RESISTANT TB in SOUTH AFRICA: Issues & Response _ ______ _____ _ ______ _____ ___ __ __ __ __ __ _______ ___ ________ ___ _______ _________ __ _____.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Multi-drug resistant tuberculosis: Progress and challenges in South Africa Dr S. Moyo HIV/AIDS, Sexually Transmitted Infections and TB research (HAST)Programme.
OECD Review of Russian Statistics Peer Review Mission to Russia April 2012 Tim Davis Head, Global Relations, Statistics Directorate.
14 th Meeting of the Core Group of the TB/HIV Working Group Addis Ababa, Ethiopia November 12, 2008 MDR and XDR-TB in the context of HIV: What next? Paul.
DOTS Expansion: Monitoring Drugs Leopold Blanc TBS, Stop TB WHO, Communicable Diseases.
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.
Session 11: MDR & XDR-TB: How Can Business Help Stem the Tide?
World Health Assembly 63 Geneva, Suisse May 2010 WORLD HEALTH EDITORS NETWORK Tracking Global Health News: building health literacy Multi-Drug Resistant.
African Business Leaders on Health: GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 11, 2010 The state of Global.
1 Oct 2005 WHO/STB/THD World Health Organization 4 th Meeting of Subgroup on laboratory capacity strengthening Paris, France, October Ernesto Jaramillo.
Tuberculosis Surveillance in Europe EuroTB update March 2008 WHO Collaborating Centre.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
TB Management: A Medical Aid Perspective presented by Dr Noluthando Nematswerani.
Strategic Information and the Control of Tuberculosis Brian Williams and Chris Dye TB programme, Monitoring and Evaluation, WHO.
Moving ahead with the Stop TB Strategy: where are we today? Dr Mario Raviglione Director, WHO Stop TB Department Joint Meeting of Core Teams and High Burden.
WHO and International Panel International Collaborative Effort on Injury Statistics Hyatt Regency, Washington September 7-8, 2006.
What are we doing about TB infection control? Bess Miller, M.D., M.Sc. Associate Director, TB/HIV Global AIDS Program Centers for Disease Control and Prevention.
Current Health Concerns: Tuberculosis Saharwash Jamali Hamna Jaffar.
Dr Ral Antic Chair Scientific Committee IUATLD-APR Australia Pre-Conference Workshop 1 National TB Control Program Summary & Remarks.
Measles Mortality Reduction: the risk of resurgence Global Immunization Meeting Geneva, Switzerland 1-3 February 2010 Balcha Masresha, WHO/AFRO.
Global Aluminium Pipe and Tube Market to 2018 (Market Size, Growth, and Forecasts in Nearly 60 Countries) Published Date: Jul-2014 Reports and Intelligence.
Measures to Decrease TB Prevalence in the Barents Region Andrey O. Maryandyshev Elena I. Nikishova Dmitry V. Perkhin.
항결핵제 감수성시험의 정도관리 2009 년 7 월 3 일 결핵연구원 김창기. 배경 Emergence of resistant tuberculosis –Multidrug-resistant tuberculosis (MDR-TB) Resistant to INH and RIF.
Christian Gunneberg, Medical Officer WHO, Geneva STB Department
SAGE 2010 Sampling Distribution
Palliative Care and M/XDR-TB Global burden of M/XDR-TB
financial requirements
reporting rate of discarded cases* per 100'000 population**
TUBERCULOSIS, TB/HIV & MDR-TB
اپيدميولوژي و كنترل سِل
PROGRESS IN GLOBAL TB CONTROL
World Health Organization
SAGE 2009 Sampling Distribution
World Health Organization
Countries Having Introduced Hib Vaccine
Countries Having Introduced Hib Vaccine and Infant Hib Coverage, 2010
Non-polio AFP Rate July 2014 – June 2015 July 2015 – June 2016
Monthly Distribution of Wild Poliovirus Cases1,
(70 countries or 36%) (23 countries or 12%)
Dr Lika Nehaul NPHS TB Lead / CCDC
Countries with Genotype data available
Countries Using Hib Vaccine in National Immunization Schedule in 2010 and Countries Approved for GAVI Support for Use from 2011 Onwards Yes (166 countries.
World Health Organization
World Health Organization
Countries having introduced HepB vaccine
Most-affected regions in the Russian Federation
Countries Using Mening Vaccine in National Immunization Schedule 2011
- Use same categories as for bar chart below Introduced Without GAVI
PROGRESS IN GLOBAL TB CONTROL
THE GLOBAL EPIDEMIOLOGY OF TUBERCULOSIS WORLD HEALTH ORGANIZATION
Meningitis/Encephalitis Surveillance Countries reporting to WHO Network or with Other (non-WHO Network) Surveillance Activities WHO Network (46 member.
2,100 4,200 1,050 Kilometers < 90% (75 countries or 39%)
World Health Organization
World Health Organization
Presentation transcript:

XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps…

Countries with XDR-TB Confirmed cases to date Czech Republic The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.  WHO All rights reserved Ecuador Georgia Argentina Bangladesh Germany Republic of Korea Armenia Russian Federation South Africa Portugal Latvia Mexico Peru USA Brazil UK Sweden Thailand Chile Based on information provided to WHO Stop TB Department 1 May 2007 Spain Islamic Republic of Iran China, Hong Kong SAR France Japan Norway Canada Italy Netherlands Estonia Lithuania Ireland Romania Israel Azerbaijan Poland Slovenia

Emergence of XDR-TB March 2006 Of 17,690 isolates from 49 countries during , 20% were MDR-TB and 2% were XDR-TB XDR-TB found in: USA: 4% of MDR-TB Latvia: 19% of MDR-TB S Korea: 15% of MDR-TB MDR-TB = resistance to at least isoniazid and rifampicin, the two most powerful first-line anti-TB drugs XDR = Multidrug-resistant TB (MDR-TB) plus resistance to (i) any fluoroquinolone, and (ii) at least 1 of 3 injectable second-line drugs capreomycin, kanamycin, amikacin (new definition agreed October 2006)

XDR-TB in Southern Africa August of 544 patients defined as XDR-TB cases 52 of the 53 patients died on average within 25 days, including those on antiretroviral therapy Further investigations being carried out XDR-TB likely in bordering African countries Church of Scotland Hospital, Tugela Ferry, KwaZulu-Natal Province, South Africa Given the underlying HIV epidemic in Africa, drug-resistant TB could have a major impact on mortality and requires urgent action on care and prevention

WHO Stop TB Strategy addresses drug resistance by strengthening TB control

The Stop TB Strategy strengthens TB control, preventing the emergence of drug-resistant TB… …and underpins the Stop TB Partnership's Global Plan to Stop TB , to treat 50 million patients and save 14 million lives The Stop TB Strategy & The Global Plan

International response to the XDR-TB emergency WHO Global Task Force on XDR-TB, October 2006 Ensure adherence to WHO drug resistance guidelines, improve programme management, access to MDR-TB drugs under proper conditions including direct observation. Ensure all patients with HIV are adequately treated for TB and started on antiretroviral therapy Accelerate implementation of infection control measures to reduce transmission especially among those HIV positive Accelerate access to rapid tests for rifampicin resistance Strengthen laboratory capacity to diagnose, manage and survey drug resistance. Commence rapid survey so that the size of the XDR-TB epidemic can be determined Initiate information-sharing strategies that promote prevention, treatment and control of XDR-TB "Priority for the immediate strengthening of TB control in countries"

Resources needed in 2007 for a global response to the XDR-TB emergency Item$ Global and regional coordination and technical support 42 million Financial needs at country level 604 million TOTAL646 million

XDR-TB The Facts Drug-resistant TB poses a grave public health threat especially in populations with high HIV rates XDR-TB occurs as a result of poorly-managed TB control programmes XDR-TB, if identified early, can be treated and cured in some cases under proper TB control conditions, based on the experiences in a few successful programmes where HIV prevalence was low Infection control measures must be strengthened everywhere, and especially where HIV prevalence is high, to protect the vulnerable and those at risk of XDR-TB XDR-TB strains have been found in all regions of the world, although still thought to be uncommon XDR-TB underlines the need for investment in the development of new TB diagnostics, treatments and vaccines, since the current tools are outdated and insufficient

World Health Organization Leading the fight against TB and XDR-TB "WHO is absolutely committed to supporting country efforts to fight TB in all forms" Dr Anders Nordström WHO Acting Director-General Address to the Global Task Force on XDR-TB "We will build greater momentum to control malaria, TB and neglected diseases" Dr Margaret Chan WHO Director-General Elect Acceptance speech to the World Health Assembly "WHO Stop TB, with full resources in place, will ensure the response to the XDR- TB emergency is effective and robust" Dr Mario Raviglione WHO Director Stop TB Department

XDR-TB For more information: WHO Stop TB: for latest XDR-TB data, country reports, monthly updates, guidelines, FAQs, Stop TB Partnership: for information on XDR-TB activities of the Partnership's Working Groups and its 500 partners